PerkinElmer, Inc. (PKI) Monday said it has completed the acquisition of ShanghaiHaoyuan Biotech Co., Ltd., a China-based infectious disease diagnostics company.
The Haoyuan acquisition enables PerkinElmer to supply advanced, highly sensitive diagnostics screenings to these banks, ensuring that HBV, HCV and HIV are accurately detected prior to transfusion.
Simultaneously, this product integration strengthens the safety of the blood banks in China while creating an opportunity for future implementation in other countries.
For comments and feedback: editorial@rttnews.com